UPDATE: Berenberg Starts Pacira Pharmaceuticals (PCRX) at Buy

April 9, 2021 6:45 AM EDT
Get Alerts PCRX Hot Sheet
Price: $59.22 +0.46%

Rating Summary:
    15 Buy, 12 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 14 | New: 23
Trade Now! 
Join SI Premium – FREE
(Updated - April 9, 2021 7:05 AM EDT)

Berenberg analyst Anita Dushyanth initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $93.00.

The analyst commented, "Pacira’s lead asset is EXPAREL, a long-acting local anaesthetic, for treatment of moderate-to-severe pain. We believe that with expanded labelling, EXPAREL could become an important part of local and regional post-operative pain treatment in the US, particularly in ambulatory surgical centres and hospital outpatient departments."

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $68.50 yesterday.

You May Also Be Interested In

Related Categories

New Coverage